Breast cancer is the most common form of malignancy in women and despite advances in diagnosis and therapy of this condition, there has been little change in the prognosis over the past 30 years (Osborne et al., 1980) . The role of the immune system in breast cancer has stimulated considerable interest and research, in particular it has been noted that breast cancer patients have demonstrably impaired cell-mediated immune responses compared to normal individuals (Whittaker & Clarke 1971) . Some workers have provided evidence that the number of thymusdependent lymphocytes (T cells) in the peripheral blood is reduced (Keller et al., 1976; Cervantes et al., 1979) while Menconi et al. (1979) showed that in advanced forms of the disease delayed hypersensitivity responses to purified-protein derivative were significantly reduced. Most attention however has focussed on in vitro functional tests of cell-mediated immunity such as the transformation of T cells by phytohaemaglutinin (PHA) which have been shown to be impaired (Conesa, 1979; Jerrells, 1978) . Zembala et al. (1977) suggested that this impaired response, evident in patients with disseminated disease, might be due to the activity of suppressor T cells in some cases.
With the introduction of monoclonal antibodies against human T lymphocyte subsets (Kung et al., 1979) it has become possible to monitor changes in the cellular immune system more definitively. These reagents were used to study breast cancer patients at all stages and for comparison with healthy females and patients suffering from benign breast disease.
Twenty-four healthy females age range 19-62 years were used as controls. They were chosen from laboratory and nursing staff and blood donors at the local blood transfusion service. Eighteen patients (age range, 19-54 years) attending the surgical outpatient clinic and diagnosed as having 0007-0920/83/020307-03 $02.00 benign breast disease were studied. Apart from the presence of a lump in the breast they were in good health and had not received any form of medical or surgical therapy for more than 3 months prior to investigation. The malignant breast disease patients Stages I-III were studied within the first 24h of admission to hospital for breast biopsy or mastectomy and investigated before any treatment. The stage of disease was determined by routine investigative procedures and operative findings. Six Stage I, 2 Stage II and 3 Stage III were studied. The 7 Stage IV breast cancer patients were studied either at first presentation (5) or at more than 6 months from preceding chemotherapy or radiotherapy (2).
Venous blood (20 ml) was aspirated from all subjects and a full blood count and differential white cell count (DWCC) performed.
Mononuclear cells were isolated from 15 ml of the peripheral venous blood by density gradient centrifugation on Ficoll Hypaque, (Boyum, 1968) washed x 2 in Eagles medium and resuspended in 0.01 M sodium phosphate buffered saline +0.1% azide (PBS) at a concentration of 5 x 106 cells ml-1. Total peripheral T cell, helper T cell (TH) and suppressor T cell (T5) subsets were estimated by indirect immunofluorescence using the OKT series of monoclonal antibodies (Orthodiagnostics, High Wycombe, U.K.) OKT3 Pan T cell, OKT4 TH cell and OKT8 for Ts cell subsets respectively, as described by Kung et al. (1979) .
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The ratio TH:TS cells is normally in the range 1:1-2:1 and this result was found in all subjects studied except for Stage IV breast cancer patients, all of whom had a TH:TS ratio of <1:1 (P <0.001).
Our findings indicate that patients with breast cancer have no reduction in the proportion or 
